Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 4Phase 1/2 4Phase 4 1Phase 3 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1

Conditions

Lymphoma, Non-Hodgkin 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × tocilizumab × 30 days × Clear all
NCT03821246 2026-06-04

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

University of California, San Francisco

Phase 2 Recruiting
68 enrolled
Genitourinary

Prostatic Neoplasms

NCT05207670 2026-06-03

MorningSun

Genentech, Inc.

Phase 2 Active not recruiting
320 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT03434730 2026-05-26

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
46 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT07589634 2026-05-15

TRI Pro

Janssen Research & Development, LLC

Phase 2 Not yet recruiting
230 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡